Calcium sequestration agents reduce skin pigmentation by inhibiting melanin formation, avoiding irritation from conventional lightening compounds.
PPARgamma agonists treat hepatic and intestinal fibrosis by decreasing alpha-SMA expression, avoiding organ transplantation.
Substituted pyridine compounds block HIF-2α/ARNT heterodimerization to treat proliferative diseases without affecting HIF-1α activity.
Topical bacterial formulations deliver CRISPR-Cas systems to modulate the skin microbiome and restore barrier integrity.
Nanoparticle-encapsulated DNA clips regulate TH promoter activity to control dopamine production, overcoming blood-brain barrier penetration limits.
Retaining inulin within intact cell walls slows intestinal passage and boosts colonic butyrate production.
Upregulating ABCF1 expression via agonists modulates immune responses, reducing neuroinflammation and cytokine levels to treat major depressive disorder.
RENADYL probiotics convert urea to nitrogen gas through fermentation, restoring kidney function while reducing toxic waste accumulation in blood.
A transdermal patch delivers naltrexone using methyl oleate or isopropyl myristate as penetration enhancers.
Substituted quinolone derivatives inhibit AXL kinase activity through localized molecular interactions.